Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of oral valproic acid to
slow the progression of visual function and/or to improve the visual function in patients
with retinitis pigmentosa (RP).
Enrolled subjects in valproic acid group will be treated with oral valproic acid 500mg daily
for 48 weeks. Visual function and safety will be assess before and after treatment (48 weeks)
between valproic acid and control groups.